| Literature DB >> 30742060 |
Xu-Hai Tan1, Xiao-Wei Zhang2, Xiao-Yun Wang2, Xiang-Qian He3, Chu Fan3, Tie-Wei Lyu1, Jie Tian4.
Abstract
Accurate evaluation of individual risk of intravenous immunoglobin (IVIG)-resistance is critical for adopting regimens for the first treatment and prevention of coronary artery lesions (CALs) in patients with Kawasaki disease (KD).Entities:
Mesh:
Substances:
Year: 2019 PMID: 30742060 PMCID: PMC6370794 DOI: 10.1038/s41598-019-39330-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Univariate analysis comparison of clinical and laboratory indexes in IVIG responsive and resistant patients.
| Variable | IVIG responsive | IVIG resistant | |||
|---|---|---|---|---|---|
| N | Mean ± SD/Counts (%) | N | Mean ± SD/Counts (%) | ||
|
| |||||
| Red blood cell count, 1012/L | 4014 | 3.98 ± 0.44 | 306 | 3.89 ± 0.47 | 0.001 |
| Absolute value of Red blood cell Distribution, fL | 3727 | 40.30 ± 4.34 | 287 | 41.12 ± 4.73 | 0.002 |
| Red blood cell distribution width, % | 3990 | 13.89 ± 1.68 | 301 | 14.30 ± 2.13 | <0.001 |
| Packed cell volume, % | 4013 | 31.99 ± 3.38 | 306 | 31.09 ± 3.70 | <0.001 |
| Erythrocyte morphology (normal/abnormal)* | 3815 | 245 (0.06) | 298 | 30 (0.10) | 0.021 |
| Mean platelet volume, fL | 3777 | 9.90 ± 1.08 | 292 | 10.11 ± 1.21 | 0.004 |
| Platelet distribution width, fL | 3882 | 11.48 ± 2.19 | 297 | 11.87 ± 2.50 | 0.002 |
| Thrombocytocrit, % | 3715 | 0.45 ± 0.56 | 280 | 0.38 ± 0.52 | <0.001 |
| Platelet count, 109/L | 4014 | 384.18 ± 155.44 | 306 | 338.13 ± 164.52 | <0.001 |
| White blood cell, 109/L | 4013 | 15.31 ± 6.24 | 306 | 15.53 ± 6.40 | 0.626 |
| Mean Corpuscular Hemoglobin, pg | 3846 | 26.28 ± 2.10 | 299 | 26.14 ± 2.16 | 0.206 |
| Lymphocyte count, 109/L | 3760 | 3.70 ± 2.02 | 293 | 2.97 ± 2.09 | <0.001 |
| Percentage of lymphocyte | 4014 | 0.26 ± 14 | 306 | 0.2 ± 0.13 | <0.001 |
| Neutrophil count, 109/L | 3927 | 10.84 ± 5.63 | 300 | 11.75 ± 5.65 | 0.004 |
| Percentage of neutrophil | 4014 | 0.69 ± 0.15 | 306 | 0.75 ± 0.15 | <0.001 |
| Monocyte count, 109/L | 3686 | 0.42 ± 0.30 | 285 | 0.42 ± 0.35 | 0.258 |
| Platelet-large-cell ratio, % | 3641 | 24.15 ± 8.15 | 282 | 25.78 ± 8.66 | 0.001 |
| Hemoglobin, g/l | 4014 | 104.26 ± 11.28 | 306 | 101.26 ± 12.05 | <0.001 |
| Lymphocyte/neutrophil, | 3757 | 0.47 ± 0.51 | 293 | 0.35 ± 0.42 | <0.001 |
|
| |||||
| Urinary bile proto (positive)* | 4536 | 100 (0.02) | 329 | 12 (0.04) | 0.135 |
| Leucocyte morphology (positive)* | 3958 | 42 (0.01) | 301 | 8 (0.03) | 0.028 |
| Hematuria (positive)* | 4536 | 282 (0.06) | 329 | 22 (0.07) | 0.824 |
| Proportion (normal/high)* | 4536 | 3014/200 (0.66/0.044) | 329 | 211/23 (0.64/0.07) | 0.095 |
| Phagocyte (positive)* | 4601 | 1 (0.00) | 330 | 1 (0.00) | 0.300 |
| Urine protein (positive)* | 4536 | 482 (0.11) | 329 | 71 (0.22) | <0.001 |
| Urobilirubin (positive)* | 4536 | 97 (0.02) | 329 | 31 (0.09) | <0.001 |
|
| |||||
| White blood cell (positive)* | 4601 | 398 (0.09) | 330 | 40 (0.12) | 0.041 |
|
| |||||
| Glutamyltranspeptidase, U/L | 4550 | 84.47 ± 110.83 | 312 | 118.00 ± 121.52 | <0.001 |
| Alanine transaminase, IU/L | 4550 | 68.13 ± 99.16 | 312 | 90.08 ± 117.16 | <0.001 |
| Aspartate aminotransferase, IU/L | 4735 | 49.44 ± 90.97 | 336 | 63.59 ± 83.64 | <0.001 |
| Lactic dehydrogenase, IU/L | 4736 | 298.33 ± 153.10 | 336 | 316.63 ± 127.08 | 0.007 |
| Alkaline phosphatase, IU/L | 4550 | 182.97 ± 127.32 | 312 | 184.18 ± 92.16 | 0.332 |
| AST/ALT | 4550 | 1.17 ± 0.83 | 312 | 1.05 ± 0.78 | 0.006 |
| Total bile acid, umol/L | 3816 | 20.56 ± 40.34 | 247 | 48.72 ± 77.35 | <0.001 |
| Direct bilirubin, umol/L | 4187 | 5.22 ± 10.03 | 280 | 10.94 ± 17.53 | <0.001 |
| Total bilirubin, umol/L | 4545 | 10.20 ± 13.08 | 312 | 18.92 ± 25.03 | <0.001 |
| Total Protein, g/L | 4550 | 59.78 ± 6.84 | 312 | 58.32 ± 9.24 | <0.001 |
| Albumin, g/L | 4550 | 36.92 ± 4.76 | 312 | 34.16 ± 5.94 | <0.001 |
| Prealbumin, mg/L | 3805 | 64.00 ± 38.47 | 244 | 54.85 ± 39.58 | <0.001 |
| Globulin, g/L | 4550 | 22.86 ± 5.23 | 312 | 24.16 ± 7.97 | 0.375 |
| Creatinine, umol/L | 4425 | 25.91 ± 15.46 | 303 | 29.75 ± 22.54 | 0.004 |
| Blood urea nitrogen, mmol/L | 4424 | 2.81 ± 1.36 | 302 | 3.50 ± 2.55 | <0.001 |
| Ketone body*, | 4536 | 0.50 ± 0.99 | 329 | 0.43 ± 0.91 | 0.469 |
| Uric acid, umol | 4423 | 208.08 ± 81.64 | 303 | 224.13 ± 100.27 | 0.036 |
|
| |||||
| C-reactive protein, mg/L | 3869 | 60.78 ± 52.32 | 296 | 73.28 ± 56.73 | <0.001 |
| Erythrocyte sedimentation rate, mm/L | 4403 | 66.50 ± 32.32 | 322 | 63.33 ± 32.82 | 0.074 |
|
| |||||
| Serum inorganic phosphorus, mmol/L | 4394 | 1.31 ± 0.29 | 306 | 1.24 ± 0.33 | <0.001 |
| Serum sodium, mmol/L | 4397 | 137.26 ± 3.17 | 306 | 135.90 ± 3.95 | <0.001 |
| Serum potassium, mmol/L | 4397 | 4.23 ± 0.66 | 306 | 4.06 ± 0.77 | <0.001 |
| Serum magnesium, mmol/L | 4395 | 0.92 ± 0.11 | 306 | 0.89 ± 0.12 | <0.001 |
| Serum chlorine, mmol/L | 4395 | 101.18 ± 3.73 | 306 | 100.84 ± 3.93 | 0.350 |
| Serum calcium, mmol/L | 4108 | 2.29 ± 0.16 | 277 | 2.23 ± 0.16 | <0.001 |
|
| |||||
| Degree of coronary artery lesions (slight/moderate/severe)* | 3745 | 1497/212/24 (0.40/0.06/0.01) | 260 | 135/39/3 (0.52/0.15/0.01) | <0.001 |
|
| |||||
| Age, month | 4928 | 31.80 ± 24.32 | 348 | 29.69 ± 25.68 | 0.016 |
| Sex (female)* | 4928 | 1893 (0.38) | 348 | 116 (0.33) | 0.067 |
| Total costs, RMB | 4929 | 11450.25 ± 3646.82 | 348 | 19637.15 ± 9207.81 | <0.001 |
| In-hospital time, day | 4929 | 7.65 ± 2.75 | 348 | 13.33 ± 6.48 | <0.001 |
ALT: Alanine transaminase; AST: Aspartate aminotransferase; *for categorical variables; N: number of sample; SD: standard deviation; W value for Wilcoxon-Mann-Whitney test; χ2 value for chi-square test.
The OR (odds ratio) values of the independent risk factors for IVIG-resistant Kawasaki disease.
| Risk factors | Multiple logistic regression analysis after LASSO | Multiple logistic regression analysis using the nine indicators with statistical significance | ||
|---|---|---|---|---|
| OR value (95% confidence interval) | OR value (95% confidence interval) | |||
| RDW | 1.181 (1.099–1.266) | <0.001 | 1.189 (1.106–1.274) | <0.001 |
| PLT | 0.999 (0.998–1.000) | 0.048 | 0.999 (0.998–1.000) | 0.013 |
| P-LYM | 0.066 (0.017–0.246) | <0.001 | 0.052 (0.013–0.193) | <0.001 |
| TBA | 1.004 (1.002–1.007) | 0.001 | 1.006 (1.003–1.008) | <0.001 |
| Na | 0.954 (0.914–0.997) | 0.034 | 0.946 (0.907–0.988) | 0.011 |
| Albumin | 0.942 (0.916–0.968) | <0.001 | 0.940 (0.915–0.967) | <0.001 |
| D-CALs1 | 2.255 (1.654–3.107) | <0.001 | 2.197 (1.616–3.019) | <0.001 |
| D-CALs2 | 2.703 (1.550–4.587) | <0.001 | 2.815 (1.630–4.738) | <0.001 |
| D-CALs3 | 5.085 (1.099–17.078) | 0.017 | 5.696 (1.234–19.078) | 0.010 |
| BUN | 1.071 (0.996–1.149) | 0.057 | / | / |
| Urobilirubin | 1.444 (0.727–2.804) | 0.285 | / | / |
| Urine protein | 1.385 (0.929–2.027) | 0.101 | / | / |
| Age | 0.462 (0.302–0.726) | 0.001 | 0.478 (0.313–0.750) | 0.001 |
LASSO, least absolute shrinkage and selection operator; RDW, red blood cell distribution width; PLT, lower platelet count; P-LYM, percentage of lymphocyte; TBA, total bile acid; Na, serum sodium level; D-CALs1, slight degree of coronary artery lesions; D-CALs2, moderate degree of coronary artery lesions; D-CALs3, severe degree of coronary artery lesions; BUN, blood urea nitrogen.
Figure 1The nomogram for personal risk probability of intravenous immunoglobin-resistant Kawasaki disease. As for age, the patients were classified as age ≤6 months and age >6 months. The risk score represents probability of intravenous immunoglobin-resistance. RDW, RBC; PLT, platelet count; P-LYM, percentage of lymphocyte; TBA, total bile acid; ALB, albumin; Na, serum sodium; D-CALs, degree of coronary artery lesions.
Figure 2ROC and AUC of the prediction models for IVIG-resistance. The new predictive model for IVIG-resistance showed an AUC of 0.74, Compared with previous IVIG-resistant scoring systems, the new model presented a higher AUC value than the Kobayashi (AUC = 0.68), Egami (AUC = 0.65), Sano (AUC = 0.55) and Yang (AUC = 0.67) methods. ROC, receiver-operator characteristic curves; AUC, area under the curve.
Figure 3AUCs of the new model by multiple testing. The AUC values of the new model tested by using the randomly-selected 30% of the whole subjects. The AUC on average was 0.72 (range 0.65–0.80).
The predictive ability of the new model and the previous models.
| The new model | Kobayashi model | Egami model | Sano model | Yang model | |
|---|---|---|---|---|---|
| Sensitivity | 0.76 | 0.75 | 0.72 | 0.95 | 0.67 |
| (95% CI) | (0.70–0.81) | (0.69–0.80) | (0.66–0.77) | (0.92–0.98) | (0.61–0.73) |
| Specificity | 0.59 | 0.48 | 0.44 | 0.1 | 0.57 |
| (95% CI) | (0.57–0.60) | (0.47–0.50) | (0.42–0.46) | (0.09–0.11) | (0.55–0.58) |
AUC, area under the curve; CI, confidence interval.